{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"570"},{"groupId":"OG001","value":"640"}],"units":"Participants"}],"description":"An adverse event is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study vaccine due to an adverse event regardless of study completion status was assessed.","groups":[{"description":"Young adult women 16- to 26-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG000","title":"Women 16-26 Years of Age"},{"description":"Adult women 27- to 45-years old received V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.","id":"OG001","title":"Women 27-45 Years of Age"}],"paramType":"NUMBER","populationDescription":"All participants that received at least 1 vaccination and had available data for endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 1 month post vaccination 3 (up to 7 months)","title":"Percentage of Participants Who Had Study Vaccine Discontinued Due to Adverse Event.","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}